NSABP B-64
NSABP B-64
Breast Cancer Clinical Validation Study to Predict Recurrence of High-Risk Early Breast Cancer Treated with Neoadjuvant Therapy Using a Bespoke Circulating Tumor DNA Assay to Detect Molecular Residual Disease
Target Accrual: 1800 patients
Status: Recruiting
ClinicialTrials.gov Identifier:
Breast Cancer Clinical Validation Study to Predict Recurrence of High-Risk Early Breast Cancer Treated with Neoadjuvant Therapy Using a Bespoke Circulating Tumor DNA Assay to Detect Molecular Residual Disease
Target Accrual: 1800 patients
Status: Recruiting
ClinicialTrials.gov Identifier: